MedTrace Logo

CML Pediatric ITK Response According to Molecular Identification at Diagnosis

NCT05605379 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2024-08-14

No results posted yet for this study

Summary

Treatment of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitor (TKI). Nevertheless, case of failure and suboptimal response are still observed even in children. Pediatric CML is a rare disease and differs from adult in terms of disease presentation and treatment response underlying a likely different CML biology. Molecular mechanisms that induce resistance to TKI are still poorly characterized except mutations in the tyrosine kinase domain of BCR::ABL1. We propose to search for a molecular signature to predict the response to TKI in the pediatric population.

Conditions

  • Chronic Myeloid Leukemia

Interventions

BIOLOGICAL

Next Generation Sequencing (DNA and RNA)

Targeted Next Generation Sequencing (DNA and RNA)

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2025-01-31
Completion
2025-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05605379 on ClinicalTrials.gov